Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $28.52 USD
Change Today +0.67 / 2.41%
Volume 152.3K
As of 8:04 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

emergent biosolutions inc (EBS) Snapshot

Open
$27.85
Previous Close
$27.85
Day High
$28.59
Day Low
$27.85
52 Week High
03/20/15 - $30.96
52 Week Low
10/15/14 - $19.31
Market Cap
1.1B
Average Volume 10 Days
324.7K
EPS TTM
$0.93
Shares Outstanding
37.9M
EX-Date
--
P/E TM
30.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for EMERGENT BIOSOLUTIONS INC (EBS)

emergent biosolutions inc (EBS) Related Businessweek News

No Related Businessweek News Found

emergent biosolutions inc (EBS) Details

Emergent BioSolutions Inc. develops, manufactures, and commercializes immunobiotics such as vaccines and immune globulins that assist the body’s immune system. The company’s biodefense segment develops, manufactures, and commercializes drugs such as BioThrax, a vaccine for the prevention of anthrax, for use against biological agents. Other products in preclinical development include drugs for the treatment of patients after they are exposed to anthrax and botulinum toxin. Emergent’s commercial segment develops products for use against infectious diseases. These include a single-dose typhoid vaccine in phase II clinical development; a hepatitis B vaccine in phase II clinical development, and a group B streptococcus vaccine for women of childbearing age for protection of the fetus and newborn babies, which is in phase I clinical trials. Emergent is also developing chlamydia and meningitis B vaccines. Emergent primarily works for the U.S. Defense and Health & Human Services departments. It has collaboration agreements with the British Health Protection Agency for the development of a human botulinum immune globulin candidate and with Sanofi Pasteur for the development of meningitis B vaccine candidate. The company, which was founded in 1998, is based in Rockville, Maryland.

1,280 Employees
Last Reported Date: 03/9/15
Founded in 1998

emergent biosolutions inc (EBS) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $1.0M
Founder, Executive Chairman and Chairman of S...
Total Annual Compensation: $726.3K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $694.2K
Executive Vice President and President of Bio...
Total Annual Compensation: $474.8K
Executive Vice President and President of Bio...
Total Annual Compensation: $138.9K
Compensation as of Fiscal Year 2013.

emergent biosolutions inc (EBS) Key Developments

Emergent BioSolutions Receives FDA Approval of Anthrasil, its Anthrax Immune Globulin Useful in the Treatment of Inhalational Anthrax

Emergent BioSolutions, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Anthrasil™ [Anthrax Immune Globulin Intravenous (Human)], also known as AIGIV, for treatment of inhalational anthrax in combination with appropriate antibacterial drugs. Anthrasil has received Orphan Drug designation and as a result of this approval, the product qualifies for seven years of market exclusivity. Anthrasil is a sterile solution of purified human immune globulin G (IgG) containing polyclonal antibodies that targets the anthrax toxins of Bacillus anthracis, the bacteria that causes anthrax disease. It is prepared using plasma collected from healthy, screened donors who have been immunized with Emergent's BioThrax® (Anthrax Vaccine Adsorbed) vaccine, the only FDA-licensed vaccine for the prevention of anthrax disease. In support of the U.S. government stockpiling strategy for AIGIV, Emergent continues to perform under a $63 million BARDA contract awarded in 2013 for the collection and storage of anti-anthrax human plasma. This plasma is necessary for the potential future manufacture of bulk drug substance and AIGIV final drug product.

Emergent BioSolutions, Inc. Wins $31 Million Contract for Advanced Development of NuThraxTM

Emergent BioSolutions, Inc. announced that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of NuThraxTM (anthrax vaccine adsorbed with CPG 7909 adjuvant), also known as AV7909, the company's next generation anthrax vaccine candidate. The contract, valued at $31 million, consists of a 30-month base period of performance to develop NuThrax for post-exposure prophylaxis of anthrax disease. Activities to be completed under the contract include process validation, consistency lot manufacture, assay validation, non-clinical studies, and start-up activities in preparation for the Phase 3 clinical trial. This contract HHSO100201500004C for the advanced development of NuThrax is funded by BARDA within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services (HHS). The Phase 2 clinical trial was conducted with support from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) of HHS under development contract number HHSN272201000035C. Contract HHSN272201400038C to develop a dry formulation of NuThrax is also administered through NIAID.

Emergent Biosolutions Inc. Manufactures a Modified Vaccinia Ankara (MVA) Ebola Zaire Vaccine Candidate (MVA EBOZ)

Emergent BioSolutions Inc. announced that, under several agreements signed with the University of Oxford, GSK, and the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) respectively, it has manufactured a modified vaccinia Ankara (MVA) Ebola Zaire vaccine candidate (MVA EBOZ) anticipated for use in a Phase 1 clinical study to be conducted by Professor Adrian Hill of the Jenner Institute. This clinical trial is being supported by a grant from the Wellcome Trust and the UK Department for International Development. The study, which will be conducted in the UK, will evaluate the safety of MVA EBOZ as a heterologous boost to GSK's Chimp Adenovirus type 3 (ChAd3) Ebola vaccine candidate. Data from an Ebola vaccine human clinical trial published recently in the New England Journal of Medicine suggest the use of an MVA vector as a potential option to boost the levels of ChAd-primed antibody and T-cell responses. Under these agreements, Emergent performed proof of concept work and manufactured the MVA EBOZ vaccine candidate at a 200L scale in an avian cell line, which had previously been licensed to the company. Manufacturing in this cell line has significant advantages including removing the requirement for eggs from the manufacturing process, consistency of manufactured vaccine lots, and increases in doses delivered. Manufacturing of the first clinical lot of the MVA EBOZ vaccine candidate is now complete and is undergoing acceptability and release testing. The scalable process has the potential to meet the demand for multi-million doses in a few months. Emergent manufactured the MVA EBOZ vaccine candidate at its Bayview Campus, Baltimore, Maryland manufacturing facility, which is equipped with disposable manufacturing technology such as single use bioreactors that enable production of viral and non-viral products with a quick turnaround. In this facility, Emergent has successfully manufactured product candidates for the company's pipeline, including MVA based vaccines. This facility has also been designated by the U.S. Department of Health and Human Services as a Center for Innovation in Advanced Development and Manufacturing (CIADM) that helps facilitate advanced development and surge manufacturing of medical countermeasures to address public health threats.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EBS:US $28.52 USD +0.67

EBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albany Molecular Research Inc $17.56 USD +0.14
Depomed Inc $22.67 USD +0.80
Flamel Technologies SA $18.00 USD +0.05
Nektar Therapeutics $11.09 USD +0.18
Skyepharma PLC 310.75 GBp -4.50
View Industry Companies
 

Industry Analysis

EBS

Industry Average

Valuation EBS Industry Range
Price/Earnings 35.6x
Price/Sales 2.4x
Price/Book 2.0x
Price/Cash Flow 29.4x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EMERGENT BIOSOLUTIONS INC, please visit www.emergentbiosolutions.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.